Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Purchased by Live Oak Private Wealth LLC

Live Oak Private Wealth LLC grew its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 11.2% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 53,355 shares of the medical equipment provider's stock after buying an additional 5,369 shares during the period. Live Oak Private Wealth LLC's holdings in Zimmer Biomet were worth $6,039,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the company. Dodge & Cox boosted its holdings in shares of Zimmer Biomet by 12.0% in the 4th quarter. Dodge & Cox now owns 19,118,436 shares of the medical equipment provider's stock valued at $2,019,480,000 after buying an additional 2,044,645 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in Zimmer Biomet by 1.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 14,760,444 shares of the medical equipment provider's stock worth $1,559,147,000 after purchasing an additional 176,337 shares in the last quarter. Franklin Resources Inc. boosted its stake in Zimmer Biomet by 398.7% in the 4th quarter. Franklin Resources Inc. now owns 3,497,764 shares of the medical equipment provider's stock worth $369,469,000 after purchasing an additional 2,796,372 shares in the last quarter. Northern Trust Corp boosted its stake in Zimmer Biomet by 7.6% in the 4th quarter. Northern Trust Corp now owns 2,370,224 shares of the medical equipment provider's stock worth $250,367,000 after purchasing an additional 167,435 shares in the last quarter. Finally, Norges Bank acquired a new stake in Zimmer Biomet in the 4th quarter worth approximately $216,223,000. 88.89% of the stock is currently owned by institutional investors.

Insider Transactions at Zimmer Biomet

In other news, insider Sang Yi sold 1,000 shares of the company's stock in a transaction on Wednesday, June 11th. The shares were sold at an average price of $95.00, for a total transaction of $95,000.00. Following the completion of the sale, the insider now owns 20,424 shares of the company's stock, valued at $1,940,280. This represents a 4.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 1.39% of the company's stock.

Wall Street Analyst Weigh In

ZBH has been the subject of a number of recent research reports. Raymond James Financial reduced their price target on shares of Zimmer Biomet from $119.00 to $104.00 and set an "outperform" rating for the company in a research report on Tuesday, May 6th. Wells Fargo & Company reduced their price target on shares of Zimmer Biomet from $113.00 to $98.00 and set an "equal weight" rating for the company in a research report on Tuesday, May 6th. Morgan Stanley reduced their price target on shares of Zimmer Biomet from $115.00 to $95.00 and set an "equal weight" rating for the company in a research report on Tuesday, May 6th. BTIG Research reissued a "buy" rating on shares of Zimmer Biomet in a research report on Monday, April 14th. Finally, Robert W. Baird reduced their price target on shares of Zimmer Biomet from $130.00 to $115.00 and set an "outperform" rating for the company in a research report on Tuesday, May 6th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, Zimmer Biomet currently has a consensus rating of "Hold" and a consensus target price of $111.53.

Zimmer Biomet Price Performance

NYSE ZBH traded down $0.86 on Thursday, hitting $91.93. The company had a trading volume of 2,822,038 shares, compared to its average volume of 1,804,453. The company has a market capitalization of $18.19 billion, a PE ratio of 20.34, a PEG ratio of 2.14 and a beta of 0.72. The company's fifty day moving average price is $94.77 and its 200-day moving average price is $102.38. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.44 and a quick ratio of 1.46. Zimmer Biomet Holdings, Inc. has a 12-month low of $89.22 and a 12-month high of $116.71.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The medical equipment provider reported $1.81 EPS for the quarter, topping the consensus estimate of $1.77 by $0.04. Zimmer Biomet had a net margin of 11.86% and a return on equity of 12.73%. The company had revenue of $1.91 billion during the quarter, compared to analyst estimates of $1.89 billion. During the same quarter in the previous year, the firm earned $1.94 EPS. The firm's revenue was up 1.1% compared to the same quarter last year. As a group, analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, July 31st. Stockholders of record on Thursday, June 26th will be issued a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.04%. The ex-dividend date is Thursday, June 26th. Zimmer Biomet's payout ratio is 21.24%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.